Trade-Ideas LLC identified

Cynosure

(

CYNO

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Cynosure as such a stock due to the following factors:

  • CYNO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.3 million.
  • CYNO has traded 124,203 shares today.
  • CYNO is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CYNO with the Ticky from Trade-Ideas. See the FREE profile for CYNO NOW at Trade-Ideas

More details on CYNO:

Cynosure, Inc. develops and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. CYNO has a PE ratio of 31. Currently there are 7 analysts that rate Cynosure a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Cynosure has been 183,400 shares per day over the past 30 days. Cynosure has a market cap of $994.2 million and is part of the health care sector and health services industry. The stock has a beta of 1.47 and a short float of 4.1% with 4.86 days to cover. Shares are up 62% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Cynosure as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

Highlights from the ratings report include:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 5.0% when compared to the same quarter one year prior, going from $3.07 million to $3.23 million.
  • CYNO's revenue growth trails the industry average of 30.2%. Since the same quarter one year prior, revenues slightly increased by 9.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
  • CYNO's debt-to-equity ratio is very low at 0.05 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, CYNO has a quick ratio of 2.07, which demonstrates the ability of the company to cover short-term liquidity needs.
  • Compared to its closing price of one year ago, CYNO's share price has jumped by 53.03%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, CYNO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.